$CFMS News

Last published 3y ago

3y agoCFMSrestor3d Completes Acquisition of ConformisGlobeNewswireDURHAM, North Carolina and BILLERICA, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following
3y agoCFMSIndependent Proxy Advisory Firms ISS and Glass Lewis Recommend Conformis Stockholders Vote "FOR" the Pending Merger with restor3dGlobeNewswireBILLERICA, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent
3y agoCFMSIndependent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote "FOR" the Pending Merger with restor3dGlobeNewswireBILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent
3y agoAMED CFMS NEX TRTNMoore Kuehn Encourages TRTN, CFMS, AMED, and NEX Investors to Contact Law FirmGlobeNewswireNEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
3y agoCFMSConformis Reports Second Quarter 2023 Financial ResultsGlobeNewswireBILLERICA, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results
3y agoCFMS NEWR PACW SURFMoore Kuehn Encourages PACW, NEWR, CFMS, and SURF Investors to Contact Law FirmGlobeNewswireNEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
3y agoCFMSConformis Announces Definitive Agreement to be Acquired by restor3d for a Purchase Price of $2.27 Per Share in CashGlobeNewswireDURHAM, N.C. and BILLERICA, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. (NASDAQ:CFMS) announced today that they have entered into a definitive merger agreement under which restor3d, a
3y agoCFMSConformis, Inc. (CFMS) Q1 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoCFMSConformis Reports First Quarter 2023 Financial ResultsGlobeNewswireBILLERICA, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for
3y agoCFMSConformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023GlobeNewswireBILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its
3y agoCFMSConformis Launches Patient Awareness Campaign to Highlight the Benefits of Personalized Knee Replacement ProceduresGlobeNewswireBILLERICA, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, recently launched a patient education
3y agoCFMSConformis, Inc. Reports Fourth Quarter and Year End 2022 Financial ResultsGlobeNewswireBILLERICA, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results
3y agoCFMSConformis, Inc. to Participate in Upcoming Investor ConferencesGlobeNewswireBILLERICA, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti,
3y agoCFMSConformis, Inc., Bodycad Laboratories, Inc. and Bodycad USA Corp. Announce Settlement of Patent LitigationGlobeNewswireBILLERICA, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) along with Bodycad Laboratories, Inc. and Bodycad USA Corp. announced today that they have entered into a settlement and license
3y agoCFMSConformis Provides Business Update and Reports Preliminary Results for Fourth Quarter and Full-Year 2022GlobeNewswireBILLERICA, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, provided today a business update and
3y agoCFMSConformis, Inc. to Announce Financial Results for Its Fourth Quarter and Full-Year 2022GlobeNewswireBILLERICA, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its
3y agoCFMSConformis, Inc. Regains Compliance with Nasdaq's Minimum Bid Price RuleGlobeNewswireBILLERICA, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it received a letter from the Listing Qualifications Department of The NASDAQ Stock Market ("NASDAQ") on November
3y agoCFMSConformis Announces First Procedure Performed Using New Actera™ Hip SystemGlobeNewswireBILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, today announced that the first procedure
3y agoCFMSConformis Announces Full Commercial Launch of Imprint™GlobeNewswireBILLERICA, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, today announced the full commercial
3y agoCFMSConformis, Inc. Announces Settlement of Medacta Patent LitigationGlobeNewswireBILLERICA, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a settlement and license agreement with Medacta USA, Medacta Germany GmbH, and Medacta
4y agoCFMSConformis, Inc. Effects 1-for-25 Reverse Stock SplitGlobeNewswireBILLERICA, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) ("Conformis") announced that it will effect a 1-for-25 reverse stock split at 5:00 p.m. Eastern time today. Beginning with the opening
4y agoCFMSConformis Reports Third Quarter 2022 Financial ResultsGlobeNewswireBILLERICA, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results
4y agoCFMSConformis, Inc. to Announce Financial Results for Its Third Quarter 2022GlobeNewswireBILLERICA, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the third quarte
4y agoCFMSConformis Actera™ Hip System Receives 510(k) Clearance from the U.S. Food and Drug AdministrationGlobeNewswireBILLERICA, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, today announced that it has received 510(k) clearance from the U.S. Food
4y agoCFMSConformis, Inc. to Participate in the H.C. Wainwright & Co. 24th Annual Global Investment ConferenceGlobeNewswireBILLERICA, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe,
4y agoCFMSConformis Reports Second Quarter 2022 Financial ResultsGlobeNewswireBILLERICA, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 3
4y agoCFMSConformis Announces New Agreement with Vizient for Personalized Orthopedic ImplantsGlobeNewswireBILLERICA, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc., (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, today announced it has entered into a multi-year agreement with Vizient,
4y agoCFMSConformis, Inc. to Participate in the Canaccord Genuity 42nd Annual Growth ConferenceGlobeNewswireBILLERICA, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe,
4y agoCFMSConformis, Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022GlobeNewswireBILLERICA, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the second quart
4y agoCFMSConformis, Inc. to Participate in the H.C. Wainwright Global Investment ConferenceGlobeNewswireBILLERICA, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe,
4y agoCFMSConformis Reports First Quarter 2022 Financial ResultsGlobeNewswireBILLERICA, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31
4y agoCFMSConformis, Inc. to Release First Quarter 2022 Financial Results on May 4, 2022GlobeNewswireBILLERICA, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today it will release its financial results for the first quarter ended March 31, 2022, before the market opens on Wednesday, May 4, 2022, at approximately 7:0
4y agoCFMSConformis, Inc. Appoints Michael Fillion as Chief Operating OfficerGlobeNewswireBILLERICA, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Michael Fillion has joined the Company as its Chief Operating Officer. "We are pleased to announce the addition of Michael Fillion as Chief Oper
4y agoCFMS SYFConformis Partners with Synchrony to Offer CareCredit Financial Services to Orthopedic PatientsGlobeNewswireBILLERICA, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), the pioneer and leader of fully personalized knee and hip replacement systems, today announced a strategic marketing partnership with Synchrony (NYSE:SYF) that will add
4y agoCFMSConformis, Inc. Appoints Denise Pedulla as Chief Legal Officer and Corporate SecretaryGlobeNewswireBILLERICA, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Denise Pedulla has joined the Company as its Chief Legal Officer and Corporate Secretary. "We are pleased to announce the addition of Denise Ped
4y agoCFMSGary Fischetti nominated to join Conformis' Board of DirectorsGlobeNewswireBILLERICA, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced today that Gary P. Fischetti has been nominated to stand for election to the Company's Board of Directors at the Company's 2022 Annual Meeting of Stockholders
4y agoCFMSConformis, Inc. Reports Fourth Quarter and Year End 2021 Financial ResultsGlobeNewswireBILLERICA, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ende
4y agoCFMSConformis Suspends All Distribution Operations and Business Development in RussiaGlobeNewswireBILLERICA, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), announced that it was suspending all distribution operations to Russia and any Russian-based entities for its orthopedic medical devices. Additionally, until further no
4y agoCFMSNew Clinical Study Finds Bilateral Knee Patients Prefer Conformis' Fully Personalized Solution Over Competitive Off-the-Shelf Implants by a Factor of Over 10 to 1GlobeNewswireBILLERICA, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), the pioneer and leader of fully personalized orthopedic medical devices, today announced results of a published retrospective study of patients showing the superiority o
4y agoCFMSConformis iTotal® CR Knee Replacement System Awarded "7A" Performance Rating from the U.K.'s Orthopaedic Data Evaluation PanelGlobeNewswireBILLERICA, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, today announced that the Orthopaedic Data Evaluation Panel in the Unit
4y agoCFMSConformis, Inc. to Participate in Upcoming Investor ConferencesGlobeNewswireBILLERICA, Mass., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe,
4y agoCFMSConformis, Inc. to Release Fourth Quarter and Fiscal Year 2021 Financial Results on March 2, 2022GlobeNewswireBILLERICA, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that as mentioned on its Business Update call on January 6, 2022, it will release its financial results for the fourth quarter and fiscal year ended Decem
4y agoCFMSConformis, Inc. Provides Business Update and Initial Expectations for 2022GlobeNewswireCompany Launches Innovative Image-to-Implant® Platinum Services℠ Program to Better Serve Patients and Surgeons BILLERICA, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features p
4y agoCFMSConformis, Inc. to Provide Business Update and Initial Expectations for 2022 on January 6, 2022GlobeNewswireBILLERICA, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it will provide a business update and initial expectations for 2022 before the market opens on Thursday, January 6, 2022, at approximately 7:00 a.m.
4y agoCFMSConformis, Inc. Announces Departure of Chief Legal Officer, Corporate SecretaryGlobeNewswireBILLERICA, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Brent Alldredge, Chief Legal Officer and Corporate Secretary, has notified the Company that he will be departing the Company on January 16, 2022 to
5y agoCFMSConformis, Inc. Appoints James Paiva as its new Vice President of U.S. Marketing; Inducement Grant ReportedGlobeNewswireBILLERICA, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed James Paiva as its new Vice President, U.S. Marketing. "Conformis is pleased to welcome James Paiva as the new V.
5y agoCFMSConformis Reports Third Quarter 2021 Financial ResultsGlobeNewswireBILLERICA, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the third quarter ended Septembe
5y agoCFMSConformis, Inc. to Release Third Quarter 2021 Financial Results on November 3, 2021GlobeNewswireBILLERICA, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it will release its financial results for the third quarter ended September 30, 2021 after the market closes on November 3, 2021 at approximately 4:0
5y agoCFMSConformis, Inc. Announces Strong Clinical Study Results for Its Personalized Knee ImplantsGlobeNewswireBILLERICA, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today the strong results of a published retrospective study of procedures using Conformis' patient-specific iTotal® CR (cruciate-retaining) knee replacement i
5y agoCFMSConformis, Inc. Provides Business UpdateGlobeNewswireBILLERICA, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) provided today an update of its third quarter revenue performance expectations in advance of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit ("OpCo Summit